Tilray Brands Reports $218 Million Q2 Revenue, Market Reacts Positively
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 20 2026
0mins
Should l Buy TLRY?
Source: Fool
- Revenue Growth: Tilray reported $218 million in revenue for Q2 of fiscal 2026, marking a record for the quarter and surpassing analyst expectations, although the year-over-year growth was only 3%, indicating cautious optimism from the market regarding its future.
- Net Loss Reduction: Despite a decline in gross margin from 29% to 26%, Tilray narrowed its net loss to $43.5 million compared to $85.3 million in the prior year, suggesting some progress in cost control measures.
- Market Opportunity: Following President Trump's executive order reclassifying cannabis as a Schedule 3 substance, Tilray plans to expand its medical cannabis operations in the U.S. with the launch of Tilray Medical USA, aiming to broaden its product portfolio and reach a wider patient base through partnerships in the medical field.
- Competitive Pressure: While Tilray faces a larger market opportunity, the increasing competition from well-established multistate operators in the U.S. necessitates that Tilray develops a competitive advantage to maintain its market share, leaving its future profitability in question.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TLRY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TLRY
Wall Street analysts forecast TLRY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLRY is 9.57 USD with a low forecast of 8.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 7.050
Low
8.50
Averages
9.57
High
10.00
Current: 7.050
Low
8.50
Averages
9.57
High
10.00
About TLRY
Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis operations, Distribution business, Beverage alcohol business and Wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The Beverage alcohol operations, which encompasses the production, marketing and sale of beverage alcohol products. The Distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers. The Wellness products, which encompasses hemp foods and cannabidiol (CBD) products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tilray Brands Rebrands Italian Medical Cannabis Unit to Expand European Footprint
- Market Restructuring: Tilray Medical Italia replaces FL Group, marking a strategic reorganization in Italy's medical cannabis sector aimed at unifying compliance platforms across key European markets and enhancing brand influence.
- Product Diversification: The new entity will offer a range of medicines approved by Italy's health authorities, including high-THC flowers and THC-CBD oil, catering to diverse medical needs while ensuring compliance with strict EU-GMP standards.
- Partnership Enhancement: Collaboration with Molteni Farmaceutici will bolster Tilray's distribution capabilities in Italy, increasing physician engagement and ensuring responsible prescribing through hospitals, doctors, and pharmacies.
- Strategic Importance: Tilray emphasizes the significance of the Italian market, committing to building a leading medical cannabis platform in Europe while supporting compliance operations in over 20 countries and promoting evidence-based therapeutic solutions.
See More
SweetWater Brewing Launches Big Trip Double IPA with 9% ABV to Strengthen Market Position
- New Product Launch: SweetWater Brewing introduces Big Trip Double IPA with a 9% ABV, aiming to capitalize on the success of its popular Daytrip IPA to further attract craft beer enthusiasts and casual drinkers.
- Market Trend Alignment: With Double IPAs trending as the second most popular craft style in the Southeast, SweetWater's launch of Big Trip strengthens its competitive position in the high-ABV beer market.
- Sales Strategy Optimization: Big Trip will be available in 19.2 oz and 6-pack 12 oz formats, aligning with the packaging preferences that account for 80% of sales for high-ABV brews in the Southeast, thereby enhancing sales performance.
- Brand Expansion Plan: SweetWater aims to enrich its product portfolio through the launch of Big Trip, solidifying its leadership position in the Southeast craft beer market while supporting its environmental initiatives.
See More
Tilray Medical Launches in Italy, Strengthening Cannabis Operations in Europe
- Brand Transformation: Tilray Medical rebrands FL Group to Tilray Medical Italia, aiming to enhance its market position in Europe through a unified medical cannabis platform, particularly in the key regulated market of Italy.
- Product Expansion: Tilray Medical Italia is expanding its footprint in Italy by launching a portfolio of medical cannabis products authorized by the Italian Ministry of Health, supported by a partnership with Molteni Farmaceutici.
- International Growth Outlook: Tilray anticipates a global medical cannabis revenue run rate of $150 million by 2026, indicating that its international expansion strategy is accelerating and further solidifying its competitive edge in the global market.
- Quarterly Revenue Surge: Tilray reported record quarterly revenue in its latest earnings report, primarily driven by growth in medical cannabis sales, showcasing the company's strong performance in the rapidly evolving medical cannabis sector.
See More
Tilray Launches Tilray Medical Italia, Expanding Medical Cannabis Operations in Italy
- Brand Transformation: Tilray rebrands FL Group to Tilray Medical Italia, reflecting its strategic commitment to the Italian medical cannabis market, aiming to enhance brand recognition and customer trust through a unified identity.
- Product Portfolio Expansion: Tilray Medical Italia launches a range of medical cannabis products authorized by the Italian Ministry of Health, including flowers with up to 25% THC and various oil concentrations, expected to significantly increase market share by catering to diverse patient needs.
- Strategic Partnership: Collaboration with leading Italian pharmaceutical company Molteni Farmaceutici ensures product quality and compliance while supporting physician education and patient access, further solidifying Tilray's market position in Italy.
- European Strategic Development: This launch is part of Tilray's broader strategy to unify its medical cannabis operations across Europe, leveraging multinational expertise and resources to drive compliant growth in 20 countries, enhancing overall business sustainability and market competitiveness.
See More
Tilray Brands Reports $217.5M Q2 Revenue, 36% Surge in International Medical Cannabis Sales
- Record Revenue: Tilray Brands reported a record revenue of $217.5 million for Q2 of fiscal 2026, reflecting a modest 3% year-over-year increase, which, while not impressive, indicates resilience in a challenging market environment that may instill some investor confidence.
- International Sales Surge: The company achieved a 36% increase in international medical cannabis sales, highlighting Tilray's potential for global market expansion, although overall growth remains lackluster, this strong performance could support future strategic initiatives.
- Improved Operating Loss: Tilray's operating loss narrowed to $22.3 million this quarter from $42.2 million a year ago, primarily due to reduced restructuring costs and amortization expenses, laying a foundation for improved profitability moving forward.
- Uncertain Market Outlook: Despite short-term gains from acquisitions and market excitement, the lack of consistent organic growth raises caution among investors regarding Tilray's long-term prospects, suggesting that significant volatility may persist in the stock's performance.
See More
Tilray Reports Record $217.5 Million Revenue in Q2 Fiscal 2026
- Record Revenue: Tilray's revenue for Q2 fiscal 2026 reached $217.5 million, marking a historic high despite only a 3% year-over-year increase, indicating some resilience in the company's market position.
- International Sales Growth: The company saw a 36% rise in international medical cannabis sales, suggesting that Tilray's global expansion strategy is beginning to yield results, although overall growth remains lackluster, reflecting efforts in product line diversification.
- Improved Operating Loss: The operating loss for the quarter was $22.3 million, an improvement from $42.2 million a year ago, primarily due to significant reductions in restructuring costs and amortization expenses, demonstrating effective cost control measures.
- Beverage Segment Decline: Despite overall revenue growth, the beverage segment experienced a 21% decline in sales to $50.1 million, indicating challenges within this business line that could impact the company's future growth potential, prompting investors to closely monitor its long-term strategic direction.
See More
Tilray Brands Rebrands Italian Medical Cannabis Unit to Expand European Footprint
- Market Restructuring: Tilray Medical Italia replaces FL Group, marking a strategic reorganization in Italy's medical cannabis sector aimed at unifying compliance platforms across key European markets and enhancing brand influence.
- Product Diversification: The new entity will offer a range of medicines approved by Italy's health authorities, including high-THC flowers and THC-CBD oil, catering to diverse medical needs while ensuring compliance with strict EU-GMP standards.
- Partnership Enhancement: Collaboration with Molteni Farmaceutici will bolster Tilray's distribution capabilities in Italy, increasing physician engagement and ensuring responsible prescribing through hospitals, doctors, and pharmacies.
- Strategic Importance: Tilray emphasizes the significance of the Italian market, committing to building a leading medical cannabis platform in Europe while supporting compliance operations in over 20 countries and promoting evidence-based therapeutic solutions.
See More
SweetWater Brewing Launches Big Trip Double IPA with 9% ABV to Strengthen Market Position
- New Product Launch: SweetWater Brewing introduces Big Trip Double IPA with a 9% ABV, aiming to capitalize on the success of its popular Daytrip IPA to further attract craft beer enthusiasts and casual drinkers.
- Market Trend Alignment: With Double IPAs trending as the second most popular craft style in the Southeast, SweetWater's launch of Big Trip strengthens its competitive position in the high-ABV beer market.
- Sales Strategy Optimization: Big Trip will be available in 19.2 oz and 6-pack 12 oz formats, aligning with the packaging preferences that account for 80% of sales for high-ABV brews in the Southeast, thereby enhancing sales performance.
- Brand Expansion Plan: SweetWater aims to enrich its product portfolio through the launch of Big Trip, solidifying its leadership position in the Southeast craft beer market while supporting its environmental initiatives.
See More
Tilray Medical Launches in Italy, Strengthening Cannabis Operations in Europe
- Brand Transformation: Tilray Medical rebrands FL Group to Tilray Medical Italia, aiming to enhance its market position in Europe through a unified medical cannabis platform, particularly in the key regulated market of Italy.
- Product Expansion: Tilray Medical Italia is expanding its footprint in Italy by launching a portfolio of medical cannabis products authorized by the Italian Ministry of Health, supported by a partnership with Molteni Farmaceutici.
- International Growth Outlook: Tilray anticipates a global medical cannabis revenue run rate of $150 million by 2026, indicating that its international expansion strategy is accelerating and further solidifying its competitive edge in the global market.
- Quarterly Revenue Surge: Tilray reported record quarterly revenue in its latest earnings report, primarily driven by growth in medical cannabis sales, showcasing the company's strong performance in the rapidly evolving medical cannabis sector.
See More
Tilray Launches Tilray Medical Italia, Expanding Medical Cannabis Operations in Italy
- Brand Transformation: Tilray rebrands FL Group to Tilray Medical Italia, reflecting its strategic commitment to the Italian medical cannabis market, aiming to enhance brand recognition and customer trust through a unified identity.
- Product Portfolio Expansion: Tilray Medical Italia launches a range of medical cannabis products authorized by the Italian Ministry of Health, including flowers with up to 25% THC and various oil concentrations, expected to significantly increase market share by catering to diverse patient needs.
- Strategic Partnership: Collaboration with leading Italian pharmaceutical company Molteni Farmaceutici ensures product quality and compliance while supporting physician education and patient access, further solidifying Tilray's market position in Italy.
- European Strategic Development: This launch is part of Tilray's broader strategy to unify its medical cannabis operations across Europe, leveraging multinational expertise and resources to drive compliant growth in 20 countries, enhancing overall business sustainability and market competitiveness.
See More
Tilray Brands Reports $217.5M Q2 Revenue, 36% Surge in International Medical Cannabis Sales
- Record Revenue: Tilray Brands reported a record revenue of $217.5 million for Q2 of fiscal 2026, reflecting a modest 3% year-over-year increase, which, while not impressive, indicates resilience in a challenging market environment that may instill some investor confidence.
- International Sales Surge: The company achieved a 36% increase in international medical cannabis sales, highlighting Tilray's potential for global market expansion, although overall growth remains lackluster, this strong performance could support future strategic initiatives.
- Improved Operating Loss: Tilray's operating loss narrowed to $22.3 million this quarter from $42.2 million a year ago, primarily due to reduced restructuring costs and amortization expenses, laying a foundation for improved profitability moving forward.
- Uncertain Market Outlook: Despite short-term gains from acquisitions and market excitement, the lack of consistent organic growth raises caution among investors regarding Tilray's long-term prospects, suggesting that significant volatility may persist in the stock's performance.
See More
Tilray Reports Record $217.5 Million Revenue in Q2 Fiscal 2026
- Record Revenue: Tilray's revenue for Q2 fiscal 2026 reached $217.5 million, marking a historic high despite only a 3% year-over-year increase, indicating some resilience in the company's market position.
- International Sales Growth: The company saw a 36% rise in international medical cannabis sales, suggesting that Tilray's global expansion strategy is beginning to yield results, although overall growth remains lackluster, reflecting efforts in product line diversification.
- Improved Operating Loss: The operating loss for the quarter was $22.3 million, an improvement from $42.2 million a year ago, primarily due to significant reductions in restructuring costs and amortization expenses, demonstrating effective cost control measures.
- Beverage Segment Decline: Despite overall revenue growth, the beverage segment experienced a 21% decline in sales to $50.1 million, indicating challenges within this business line that could impact the company's future growth potential, prompting investors to closely monitor its long-term strategic direction.
See More
